The Science
GEM Pharma has established a robust and versatile drug discovery and development platform based on proprietary technologies, broad licenses to fundamental intellectual property and extensive scientific expertise after more than four decades working on influencing the production level of protein in the cell to achieve healing via regulation of gene expression without interfering with genetics.
TREAT INFLAMMATION
VIA mRNA CALIBRATION
GEM Pharma is a pharmaceutical company that develops and brings to market safe, affordable medications for inflammatory conditions based on the unique Gene Expression Modification platform.
About Us
GEM Pharma is a spinoff of Resdevco Ltd. a pharmaceutical research company that was established over 40 years ago. The pioneering research was developed by Prof. Shabtay Dikstein (Prof. Emeritus) of the Hebrew University. Recognized by the university and internationally as a creative, groundbreaking inventor and innovator. The strength of GEM Pharma lies not only on the innovative and groundbreaking G.E.M platform but also on the strong network of professionals that has been built over the last three decades.
Erez Meltzer
EXECUTIVE CHAIRMAN
Dani Shomron
CEO - DIRECTOR R&D
Dr. Liat Lomnitski
DIRECTOR OF SAFTEY ASSESSMENT, REGULATORY, TOXICOLOGY,
Prof. Tamas Biro
CHIEF SCIENTIFIC OFFICER
Prof. Eran Goldin
CHIEF MEDICAL OFFICER
Dr. G. Bartus
QUALITY DIRECTOR AND FORMULATION
Dr. Susanne Mair
DIRECTOR OF SALES AND MARKET STUDIES
Pipeline
Our platform is potentially applicable to a broad range of diseases caused by insufficient protein production or where production of proteins can modify the disease. The depth and versatility of our technologies enable us to address conditions in virtually any therapeutic area.
